CA
NZ
UK
AU
IND
US
These patent actions, issued across key international markets including the United States, Canada, and Japan, bring Phio's total issued patent portfolio to 54 patents — a substantial intellectual property estate for a clinical-stage biotech company of Phio's size. The robust IP package comprehensively covers …
Gossamer Bio has obtained the capability to issue up to 4,000,000,000 shares of common stock, a roughly sixfold increase that clears the path for a $72.0 million convertible debt exchange and a block of 135,789,000 purchase warrants.
Lexeo Therapeutics (NASDAQ: LXEO) remains one of the best stocks under $10 with potential to triple, even after JPMorgan slashed its price target by a quarter. The clinical-stage biotech, trading near $4.54, still offers over 92% upside to the revised $9 target, reflecting confidence …
Palvella Therapeutics Inc. (NASDAQ: PVLA) submitted the first module of its New Drug Application for QTORIN on June 29, moving the company closer to market entry for a therapy targeting microcystic lymphatic malformations. The filing follows a rolling review granted on June 22 and …
Praxis Precision Medicines recently released its earnings results for the most recent quarter, posting a loss per share that was more favorable than what analysts had projected. While the specific monetary values are not disclosed here, the beat underscores a degree of financial resilience …
Verastem’s stock target was trimmed by RBC Capital, yet the firm maintained its Outperform rating, leaving investors with a potential 211% upside. The adjustment reflects broader biotech sector caution ahead of second-quarter earnings, though the company’s experimental cancer therapies continue to draw attention.
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) has appointed Donn Casale as its new CEO and Director, effective July 7, following a transition period that began on July 6. The company's shares fell 4.6% to $7.26 in recent trading, reflecting a 36.8% decline year-to-date. This leadership …
Beam Therapeutics (NASDAQ: BEAM) secured a Buy rating from Bank of America Securities with a $47 price target, indicating more than 33% upside from current levels. Shares slipped 0.8% to $30.63 in recent trading, while the stock remains up 12.9% year‑to‑date and 5.5% over …
Cannara's Q3 2026 revenue growth of 16% has sent a positive signal to the healthcare sector. The company's performance indicates a strong demand for its products and services. This growth is expected to have a ripple effect on the sector, with other companies likely …
Elevance Health (NYSE: ELV) posted its quarterly performance for the period that closed on June 30, 2026, with the results made public on July 15, 2026. The release offers investors a snapshot of the company’s recent activity and sets the tone for the next …
Please wait processing your request...